Gilead Sciences (GILD) Downgraded by TheStreet

Gilead Sciences (NASDAQ:GILD) was downgraded by equities research analysts at TheStreet from a “b-” rating to a “c” rating in a research note issued on Tuesday.

GILD has been the subject of a number of other research reports. Berenberg Bank set a $96.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Thursday, October 19th. JPMorgan Chase & Co. set a $85.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a report on Wednesday, October 25th. Credit Suisse Group restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a report on Thursday, December 7th. Zacks Investment Research cut shares of Gilead Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, December 27th. Finally, Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 price objective for the company in a report on Friday, October 13th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $86.56.

Shares of Gilead Sciences (GILD) traded up $1.10 during midday trading on Tuesday, reaching $79.32. 13,750,000 shares of the company were exchanged, compared to its average volume of 9,910,000. The firm has a market capitalization of $103,590.00, a PE ratio of 22.79, a P/E/G ratio of -1.75 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.55. Gilead Sciences has a 52-week low of $63.76 and a 52-week high of $89.54.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to analysts’ expectations of $5.71 billion. Gilead Sciences had a net margin of 17.73% and a return on equity of 50.29%. The business’s revenue for the quarter was down 18.7% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.70 earnings per share. analysts forecast that Gilead Sciences will post 6.41 EPS for the current year.

In other news, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the sale, the executive vice president now owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $83.51, for a total transaction of $2,087,750.00. Following the completion of the sale, the executive vice president now directly owns 62,738 shares in the company, valued at approximately $5,239,250.38. The disclosure for this sale can be found here. In the last three months, insiders sold 578,333 shares of company stock worth $44,100,508. 1.30% of the stock is currently owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Capital International Investors raised its position in Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after acquiring an additional 5,205,983 shares in the last quarter. Sanders Capital LLC raised its position in Gilead Sciences by 102.9% during the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock worth $757,119,000 after acquiring an additional 5,026,015 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its position in Gilead Sciences by 230.0% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock worth $399,233,000 after acquiring an additional 3,434,450 shares in the last quarter. CI Global Investments Inc. raised its position in Gilead Sciences by 5,461.1% during the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock worth $237,675,000 after acquiring an additional 3,257,969 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership raised its position in Gilead Sciences by 12,545.5% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 3,070,327 shares of the biopharmaceutical company’s stock worth $219,958,000 after acquiring an additional 3,046,047 shares in the last quarter. 75.84% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Gilead Sciences (GILD) Downgraded by TheStreet” was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/02/11/gilead-sciences-gild-downgraded-by-thestreet.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply